Genetic testing requirements for giritinib/segatan

Gilitinib is an oral small molecule tyrosine kinase inhibitor mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3 gene mutations. FLT3 gene mutation is one of the most common driver mutations in AML, and its presence is closely related to increased disease aggressiveness and increased risk of recurrence. Therefore, genetic testing before using giritinib is the basis for precise treatment and an important prerequisite to ensure the effectiveness and safety of the drug.

In clinical practice, doctors usually conduct bone marrow aspiration or peripheral blood samples for FLT3 gene testing, including detection of ITD (internal tandem duplication) and TKD (tyrosine kinase domain) mutations. These mutation types differ in their sensitivity to giritinib, with FLT3-ITD-positive patients generally responding more significantly to giritinib. The test results not only determine whether the patient is suitable for medication, but also provide a reference for formulating dosage and treatment plans.

In addition toFLT3 mutation status, patients also need to undergo hematological evaluation, liver and kidney function tests, and cardiac function evaluation before treatment. These basic examinations can help doctors understand the patient's overall health status and monitor potential adverse reactions during medication, such as thrombocytopenia, neutropenia, or elevated liver enzymes. It is worth noting that giritinib is only suitable for patients with relapsed or refractory AML who are positive for FLT3 mutations. For patients with undetected FLT3 mutations, its efficacy is significantly reduced, so genetic testing is an indispensable step.

With the development of precision medicine, genetic testing methods have become increasingly diversified, including real-time fluorescence quantitativePCR, next-generation sequencing (NGS) and other technologies. These technologies can quickly and accurately assess FLT3 mutation status, provide a reliable basis for the application of giritinib, and can also monitor changes in mutation load during treatment and provide a reference for treatment plan adjustment.

Reference materials:https://www.xospata.com/